Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1995 Dec;96(6):2711–2718. doi: 10.1172/JCI118338

Anti-thrombotic effects of a nitric oxide-releasing, gastric-sparing aspirin derivative.

J L Wallace 1, W McKnight 1, P Del Soldato 1, A R Baydoun 1, G Cirino 1
PMCID: PMC185978  PMID: 8675638

Abstract

Effects of a nitroxybutylester derivative of aspirin (NCX 4215) on platelet aggregation and prostanoid synthesis were compared to the effects of aspirin. NCX 4215 was approximately seven times more potent than aspirin as an inhibitor of thrombin-induced human platelet aggregation in vitro, but did not inhibit platelet thromboxane synthesis or gastric prostaglandin synthesis. NCX 4215 released nitric oxide when incubated in the presence of platelets and increased platelet levels of cGMP within 10 min of exposure, while aspirin did not. The anti-aggregatory effects of NCX 4215 in vitro were significantly attenuated by 10 microM hemoglobin. In ex vivo studies of ADP- or collagen- or thrombin-induced rat platelet aggregation, aspirin and NCX 4215 had comparable inhibitory effects 3 h after administration. Aspirin (10-120 mg/kg) caused extensive hemorrhagic erosion formation in the stomach of the rat within 3 h of oral administration, while NCX 4215 did not produce significant damage at doses of up to 300 mg/kg, nor when given daily for two weeks at 166 mg/kg. NCX 4215 did not alter systemic arterial blood pressure when administered intravenously to the rat. These studies demonstrate that NCX 4215 has comparable or enhanced anti-thrombotic activity to that of aspirin, but does not cause gastric damage or alter systemic blood pressure. The anti-thrombotic actions of NCX 4215 are, at least in part, due to generation of nitric oxide.

Full text

PDF
2711

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. DODGSON K. S., SPENCER B. Studies on sulphatases. VII. A preliminary account of the glycosulphatase of Littorina littorea. Biochem J. 1954 Jun;57(2):310–315. doi: 10.1042/bj0570310. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Hall D., Zeitler H., Rudolph W. Counteraction of the vasodilator effects of enalapril by aspirin in severe heart failure. J Am Coll Cardiol. 1992 Dec;20(7):1549–1555. doi: 10.1016/0735-1097(92)90449-w. [DOI] [PubMed] [Google Scholar]
  3. Hogaboam C. M., Befus A. D., Wallace J. L. Modulation of rat mast cell reactivity by IL-1 beta. Divergent effects on nitric oxide and platelet-activating factor release. J Immunol. 1993 Oct 1;151(7):3767–3774. [PubMed] [Google Scholar]
  4. Kurata J. H., Abbey D. E. The effect of chronic aspirin use on duodenal and gastric ulcer hospitalizations. J Clin Gastroenterol. 1990 Jun;12(3):260–266. doi: 10.1097/00004836-199006000-00005. [DOI] [PubMed] [Google Scholar]
  5. Lee M., Cryer B., Feldman M. Dose effects of aspirin on gastric prostaglandins and stomach mucosal injury. Ann Intern Med. 1994 Feb 1;120(3):184–189. doi: 10.7326/0003-4819-120-3-199402010-00002. [DOI] [PubMed] [Google Scholar]
  6. Leivonen M., Sipponen P., Kivilaakso E. Gastric changes in coronary-operated patients with low-dose aspirin. Scand J Gastroenterol. 1992 Nov;27(11):912–916. doi: 10.3109/00365529209000162. [DOI] [PubMed] [Google Scholar]
  7. Martin W., Villani G. M., Jothianandan D., Furchgott R. F. Selective blockade of endothelium-dependent and glyceryl trinitrate-induced relaxation by hemoglobin and by methylene blue in the rabbit aorta. J Pharmacol Exp Ther. 1985 Mar;232(3):708–716. [PubMed] [Google Scholar]
  8. Meade T. W., Roderick P. J., Brennan P. J., Wilkes H. C., Kelleher C. C. Extra-cranial bleeding and other symptoms due to low dose aspirin and low intensity oral anticoagulation. Thromb Haemost. 1992 Jul 6;68(1):1–6. [PubMed] [Google Scholar]
  9. Oates J. A., FitzGerald G. A., Branch R. A., Jackson E. K., Knapp H. R., Roberts L. J., 2nd Clinical implications of prostaglandin and thromboxane A2 formation (2). N Engl J Med. 1988 Sep 22;319(12):761–767. doi: 10.1056/NEJM198809223191206. [DOI] [PubMed] [Google Scholar]
  10. Palmer R. M., Ferrige A. G., Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature. 1987 Jun 11;327(6122):524–526. doi: 10.1038/327524a0. [DOI] [PubMed] [Google Scholar]
  11. Patrono C. Aspirin as an antiplatelet drug. N Engl J Med. 1994 May 5;330(18):1287–1294. doi: 10.1056/NEJM199405053301808. [DOI] [PubMed] [Google Scholar]
  12. Patrono C., Ciabattoni G., Pinca E., Pugliese F., Castrucci G., De Salvo A., Satta M. A., Peskar B. A. Low dose aspirin and inhibition of thromboxane B2 production in healthy subjects. Thromb Res. 1980 Feb 1;17(3-4):317–327. doi: 10.1016/0049-3848(80)90066-3. [DOI] [PubMed] [Google Scholar]
  13. Patrono C., Dunn M. J. The clinical significance of inhibition of renal prostaglandin synthesis. Kidney Int. 1987 Jul;32(1):1–12. doi: 10.1038/ki.1987.164. [DOI] [PubMed] [Google Scholar]
  14. Radomski M. W., Palmer R. M., Moncada S. Comparative pharmacology of endothelium-derived relaxing factor, nitric oxide and prostacyclin in platelets. Br J Pharmacol. 1987 Sep;92(1):181–187. doi: 10.1111/j.1476-5381.1987.tb11310.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Radomski M. W., Palmer R. M., Moncada S. The anti-aggregating properties of vascular endothelium: interactions between prostacyclin and nitric oxide. Br J Pharmacol. 1987 Nov;92(3):639–646. doi: 10.1111/j.1476-5381.1987.tb11367.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Radomski M., Moncada S. An improved method for washing of human platelets with prostacyclin. Thromb Res. 1983 May 15;30(4):383–389. doi: 10.1016/0049-3848(83)90230-x. [DOI] [PubMed] [Google Scholar]
  17. Segasothy M., Samad S. A., Zulfigar A., Bennett W. M. Chronic renal disease and papillary necrosis associated with the long-term use of nonsteroidal anti-inflammatory drugs as the sole or predominant analgesic. Am J Kidney Dis. 1994 Jul;24(1):17–24. doi: 10.1016/s0272-6386(12)80155-7. [DOI] [PubMed] [Google Scholar]
  18. Vane J. R. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol. 1971 Jun 23;231(25):232–235. doi: 10.1038/newbio231232a0. [DOI] [PubMed] [Google Scholar]
  19. Wallace J. L. Gastric ulceration: critical events at the neutrophil--endothelium interface. Can J Physiol Pharmacol. 1993 Jan;71(1):98–102. doi: 10.1139/y93-014. [DOI] [PubMed] [Google Scholar]
  20. Wallace J. L., Reuter B., Cicala C., McKnight W., Grisham M. B., Cirino G. Novel nonsteroidal anti-inflammatory drug derivatives with markedly reduced ulcerogenic properties in the rat. Gastroenterology. 1994 Jul;107(1):173–179. doi: 10.1016/0016-5085(94)90074-4. [DOI] [PubMed] [Google Scholar]
  21. Wallace J. L., Reuter B., Cicala C., McKnight W., Grisham M., Cirino G. A diclofenac derivative without ulcerogenic properties. Eur J Pharmacol. 1994 May 23;257(3):249–255. doi: 10.1016/0014-2999(94)90136-8. [DOI] [PubMed] [Google Scholar]
  22. Wallace J. L., Whittle B. J. Role of prostanoids in the protective actions of BW755C on the gastric mucosa. Eur J Pharmacol. 1985 Sep 10;115(1):45–52. doi: 10.1016/0014-2999(85)90582-5. [DOI] [PubMed] [Google Scholar]
  23. Ware J. A., Heistad D. D. Seminars in medicine of the Beth Israel Hospital, Boston. Platelet-endothelium interactions. N Engl J Med. 1993 Mar 4;328(9):628–635. doi: 10.1056/NEJM199303043280907. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES